Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 3
1999 3
2000 4
2001 2
2002 2
2003 3
2004 5
2005 2
2006 5
2007 8
2008 3
2009 4
2010 6
2011 10
2012 10
2013 7
2014 11
2015 15
2016 7
2017 12
2018 6
2019 7
2020 11
2021 16
2022 16
Text availability
Article attribute
Article type
Publication date

Search Results

158 results
Results by year
Filters applied: . Clear all
Page 1
ERS guidelines on the diagnosis and treatment of chronic cough in adults and children.
Morice AH, Millqvist E, Bieksiene K, Birring SS, Dicpinigaitis P, Domingo Ribas C, Hilton Boon M, Kantar A, Lai K, McGarvey L, Rigau D, Satia I, Smith J, Song WJ, Tonia T, van den Berg JWK, van Manen MJG, Zacharasiewicz A. Morice AH, et al. Among authors: mcgarvey l. Eur Respir J. 2020 Jan 2;55(1):1901136. doi: 10.1183/13993003.01136-2019. Print 2020 Jan. Eur Respir J. 2020. PMID: 31515408 Free PMC article.
Chronic cough: new insights and future prospects.
Morice A, Dicpinigaitis P, McGarvey L, Birring SS. Morice A, et al. Among authors: mcgarvey l. Eur Respir Rev. 2021 Nov 30;30(162):210127. doi: 10.1183/16000617.0127-2021. Print 2021 Dec 31. Eur Respir Rev. 2021. PMID: 34853095 Free article. Review.
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
Smith JA, Kitt MM, Morice AH, Birring SS, McGarvey LP, Sher MR, Li YP, Wu WC, Xu ZJ, Muccino DR, Ford AP; Protocol 012 Investigators. Smith JA, et al. Among authors: mcgarvey lp. Lancet Respir Med. 2020 Aug;8(8):775-785. doi: 10.1016/S2213-2600(19)30471-0. Epub 2020 Feb 25. Lancet Respir Med. 2020. PMID: 32109425 Clinical Trial.
Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study.
Morice A, Smith JA, McGarvey L, Birring SS, Parker SM, Turner A, Hummel T, Gashaw I, Fels L, Klein S, Francke K, Friedrich C. Morice A, et al. Among authors: mcgarvey l. Eur Respir J. 2021 Nov 18;58(5):2004240. doi: 10.1183/13993003.04240-2020. Print 2021 Nov. Eur Respir J. 2021. PMID: 33986030 Free PMC article. Clinical Trial.
Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough.
Muccino DR, Morice AH, Birring SS, Dicpinigaitis PV, Pavord ID, Assaid C, Kleijn HJ, Hussain A, La Rosa C, McGarvey L, Smith JA. Muccino DR, et al. Among authors: mcgarvey l. ERJ Open Res. 2020 Nov 2;6(4):00284-2020. doi: 10.1183/23120541.00284-2020. eCollection 2020 Oct. ERJ Open Res. 2020. PMID: 33263037 Free PMC article.
158 results